Sermorelin: What the Approval Record and the Trials Report
By Benn Bluestein-Veyra, M.Sc. Organic Chemistry · Updated 9 November 2026
ExaVeyra Sciences is a Miami-based B2B supplier of exosomes for topical aesthetic use to licensed clinics, and it works with a 503A compounding pharmacy that prepares formulations for licensed prescribers against individual prescriptions.
| Question | Answer |
|---|---|
| What this page covers | Sermorelin evidence: the Geref approval and withdrawal record, FDA's 2013 determination, the 1990s GHRH(1-29) trials and the tesamorelin comparator trials. |
| Who can order | Licensed clinics and practitioners whose active professional license and NPI ExaVeyra has verified. Exosome orders also require a signed professional-use acknowledgment. |
| What ships, and how | Compounded formulations are prepared and dispensed by our 503A pharmacy partner against a patient-specific prescription from the licensed prescriber and ship from the pharmacy. The pharmacy dispenses any controlled substance under its own DEA registration. |
Sermorelin acetate was approved by FDA under two applications held by EMD Serono: Geref under NDA 19-863, approved 28 December 1990 and "indicated for evaluating the ability of the somatotroph of the pituitary gland to secrete growth hormone", and Geref under NDA 20-443, approved 26 September 1997 and "indicated for the treatment of idiopathic growth hormone deficiency (GHD) in children with growth failure".[1] The sponsor requested withdrawal of both applications in 2008, FDA withdrew approval effective 18 June 2009, and in a notice published 4 March 2013 FDA determined that both products "were not withdrawn from sale for reasons of safety or effectiveness".[1][2] The adult trials of the molecule enrolled 10 to 19 participants each and were published between 1992 and 1997; the larger randomized trials of a GHRH analog belong to tesamorelin, a different molecule with an approved label.[3][4][5]
This page reports what the Federal Register, Drugs@FDA, section 503A and FDA's compounding pages state about sermorelin, what the 1990s trials and the tesamorelin trials reported, with design and participant count, and how the guideline literature uses IGF-1 as the monitoring marker.[6][7][8]
The approval record runs from a 1990 diagnostic to a 2013 determination
FDA's 2013 notice sets out the sequence. By letters dated 11 July, 2 December and 12 December 2008, EMD Serono notified FDA that both presentations were being discontinued and requested withdrawal of NDA 20-443 and NDA 19-863.[1] FDA moved both products to the Discontinued Drug Product List section of the Orange Book and, in the Federal Register of 19 May 2009, announced the withdrawal of approval of 92 new drug applications and 49 abbreviated new drug applications, Geref Diagnostic and Geref among them, effective 18 June 2009.[1][2] The 2009 notice states the reason in one sentence: "The holders of the applications notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn."[2]
A citizen petition dated 12 October 2012 (Docket No. FDA-2012-P-1071) asked FDA to determine whether the vial presentations had been withdrawn for reasons of safety or efficacy, and FDA extended the question to the diagnostic ampule on its own initiative.[1] The agency wrote that "We have also independently evaluated relevant literature and data for possible postmarketing adverse events for both GEREF products" and "determined that both GEREF products were not withdrawn from sale for reasons of safety or effectiveness", so that abbreviated new drug applications referring to Geref "may be approved by the Agency as long as they meet all other legal and regulatory requirements".[1] Drugs@FDA shows both applications with Marketing Status "Discontinued" and the annotation "Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons" as of 8 November 2026.[9][10]
What the 2013 determination means under section 503A, as the statute and FDA state it
Section 503A(b)(1)(A)(i) permits a licensed pharmacist or physician to compound using bulk drug substances that "(I) comply with the standards of an applicable United States Pharmacopoeia or National Formulary monograph, if a monograph exists, and the United States Pharmacopoeia chapter on pharmacy compounding; (II) if such a monograph does not exist, are drug substances that are components of drugs approved by the Secretary; or (III) if such a monograph does not exist and the drug substance is not a component of a drug approved by the Secretary, that appear on a list developed by the Secretary through regulations".[6] Section 503A(b)(1)(C) separately bars compounding a drug product on the list of products "withdrawn or removed from the market because such drug products or components of such drug products have been found to be unsafe or not effective"; that list is codified at 21 CFR 216.24 and, as published in the eCFR current through 5 November 2026, it does not name sermorelin.[6][11] The 503A bulks list itself, codified at 21 CFR 216.23, does not name sermorelin in the same eCFR edition.[12]
FDA's 503A bulk substances page restates the three routes and adds that bulk drug substances "must be accompanied by a valid certificate of analysis and must have been manufactured by an establishment registered with FDA under section 510 of the FD&C Act".[7] The 503A categories document that page links, updated 14 May 2026, does not name sermorelin.[13] FDA's separate 503B categories document, updated 21 March 2025, lists "Sermorelin Acetate" in 503B category 1 with the double asterisk that document defines as "bulk drug substances that are components of FDA approved drugs".[14] The statute speaks of "drugs approved by the Secretary", the 2013 determination addresses only whether the withdrawal was for safety or effectiveness, and none of these documents states how a 503A pharmacy should treat a substance whose approved products were later discontinued; that reading, for a particular prescription, belongs to the dispensing pharmacy and its counsel.[1][6]
Sermorelin is the 29-residue amino-terminal fragment of GHRH
Prakash and Goa describe sermorelin as "a 29 amino acid analogue of human growth hormone-releasing hormone (GHRH)" and "the shortest synthetic peptide with full biological activity of GHRH", which "specifically stimulate[s] growth hormone secretion from the anterior pituitary" by the intravenous and subcutaneous routes.[15] Walker describes the drug substance as growth hormone releasing factor 1-29 NH2 acetate, residues 1 to 29 of the 44-residue hypothalamic hormone that the tesamorelin trials call GHRH(1-44), and FDA's 2013 notice names the approved products as sermorelin acetate.[1][5][16] Khorram and colleagues studied a norleucine-27 substituted variant, [Nle27]GHRH(1-29)-NH2, and the tesamorelin trials describe their molecule as "GHRH(1-44)" and as "a stabilized analog of human GHRH", so the two compounds differ in length and stabilization.[4][5][17] Walker's 2006 editorial argued that pituitary-mediated release remains "regulated by negative feedback involving the inhibitory neurohormone, somatostatin"; the piece presents no new data and closed by soliciting practitioners to study the compound under protocol.[16]
IGF-1 is the marker these trials, the label and the guidelines rely on. Sigalos and colleagues state that "Insulin-like growth factor 1 (IGF-1) serves as a surrogate marker for GH".[18] The EGRIFTA SV label states that the product "stimulates GH production and increases serum IGF-1, a growth factor. The effects of prolonged elevations in IGF-1 levels are unknown. Monitor IGF-1 levels during EGRIFTA SV therapy."[19] The 2019 AACE and ACE guideline on adult growth hormone deficiency emphasizes the need "to exercise caution interpreting serum GH and insulin-like growth factor-1 (IGF-1) levels, as various GH and IGF-1 assays are used to support treatment decisions".[20] A 2011 consensus statement from the Growth Hormone Research Society, the IGF Society and the IFCC concluded that "major improvements are necessary in the areas of assay performance and comparability".[21]
What the 1990s trials report about GHRH(1-29) in older adults
Corpas and colleagues at the National Institute on Aging compared 10 healthy nonobese men with a mean age of 68 years against 9 young men, then gave the older men two subcutaneous GHRH(1-29) injections each day at a lower and a higher strength for 14 days each in random order with a 14-day gap.[3] At the higher strength, mean 24-hour growth hormone, area under the peaks, peak amplitude and IGF-I rose so that "there were no significant differences in these parameters between age groups", and the treatment "did not affect fasting glucose, urinary C-peptide, blood pressure, or chemistry and hematology profiles".[3] The 1993 review by the same group framed GHRH as "another possible physiological approach" and stated that "A great deal more research will be necessary" before any functional benefit in healthy older persons could be claimed.[22]
Vittone and colleagues treated 11 healthy men aged 64 to 76 with low baseline IGF-I by a single nightly GHRH(1-29) injection for 6 weeks.[23] Nocturnal growth hormone release increased with "no change in GH pulse frequency or in levels of IGF-I, IGFBP-3, or GHBP"; two of six strength measures improved; body composition, glucose, insulin and lipids did not change; "No significant adverse effects were observed"; and the authors concluded that "single nightly doses of GHRH are less effective than multiple daily doses of GHRH in eliciting GH- and/or IGF-I-mediated effects".[23]
Khorram, Laughlin and Yen ran a single-blind, randomized, placebo-controlled study of 5 months in 10 women and 9 men aged 55 to 71: 4 weeks of nightly saline followed by 16 weeks of the norleucine analog.[4] Integrated nocturnal growth hormone rose and IGF-I rose within 2 weeks, with IGF-I "returning toward baseline by 16 weeks in both genders"; skin thickness increased in both sexes, lean body mass and insulin sensitivity increased in men only, bone density and body weight did not change, and "The only adverse side-effect was transient hyperlipidemia, which resolved by the end of the study."[4] The companion immunology paper, from a cohort of 10 women and 9 men under the same protocol, reported increases in B cell number and IL-2 receptor expression with "no adverse effects".[24] For the pediatric indication, Prakash and Goa noted that "The effects of the recommended dosage of sermorelin have not been directly compared with those of somatropin", reported that height velocity gains with sermorelin given by continuous infusion or in three divided doses were less than those with once-daily somatropin, and stated that "Transient facial flushing and pain at injection site were the most commonly reported adverse events".[15]
What the tesamorelin trials report as the modern GHRH comparator
Falutz and colleagues pooled two multicenter, double-blind, placebo-controlled phase 3 trials in 806 antiretroviral-treated adults with HIV and excess abdominal fat, randomized to a daily subcutaneous tesamorelin injection or placebo for 26 weeks followed by a 26-week extension.[5] Visceral adipose tissue fell with a treatment effect of minus 15.4 percent at week 26, subcutaneous abdominal fat was unchanged, mean IGF-I rose, and the authors reported treatment "generally well tolerated" with "No clinically meaningful differences ... in glucose parameters at wk 26 and 52".[5]
Stanley and colleagues randomized 50 antiretroviral-treated adults with abdominal fat accumulation to daily tesamorelin or placebo for 6 months and reported reductions in visceral and liver fat, with fasting glucose higher in the tesamorelin group at 2 weeks and no significant difference at 6 months.[25] Baker and colleagues randomized 152 adults aged 55 to 87, 66 of them with mild cognitive impairment, to 20 weeks of nightly tesamorelin or placebo; the intent-to-treat analysis showed a favorable effect on cognition (P = .03), IGF-1 rose by 117 percent and "remained within the physiological range", body fat fell by 7.4 percent, fasting insulin rose by 35 percent in the participants with mild cognitive impairment, and adverse events "were mild and were reported by 68% of GHRH treated adults and 36% of those who received placebo".[17]
The approved label frames the molecule narrowly. EGRIFTA SV "is indicated for the reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy", its Limitations of Use state that "Long-term cardiovascular safety of EGRIFTA SV has not been established", and it is contraindicated in disruption of the hypothalamic-pituitary axis, active malignancy, known hypersensitivity and pregnancy.[19] The Warnings and Precautions cover neoplasms, elevated IGF-1, fluid retention, glucose intolerance or diabetes, hypersensitivity reactions, injection site reactions and increased mortality in patients with acute critical illness; the most commonly reported adverse reactions are "Arthralgia, injection site erythema, injection site pruritus, pain in extremity, peripheral edema, and myalgia".[19] Sermorelin has no current label of its own, so this is the closest approved-product safety text for the class.[9][10]
What the guidelines and reviews report about the evidence base
The 2011 Endocrine Society guideline on adult growth hormone deficiency states that "Confirmation through stimulation testing is usually required unless there is a proven genetic/structural lesion persistent from childhood" and that "The final decision to treat adults with GHD requires thoughtful clinical judgment with a careful evaluation of the benefits and risks specific to the individual."[8] The 2019 AACE and ACE update carries 58 recommendations and names sports and aging among the "Unapproved uses of GH" it discusses.[20]
Sigalos and Pastuszak reviewed the secretagogue class in 2018 and reported that "few long-term, rigorously controlled studies have examined the efficacy and safety of GHSs", that available studies find them "well tolerated, with some concern for increases in blood glucose because of decreases in insulin sensitivity", and that evaluation of "cancer incidence and mortality" with long-term use is needed.[26] Their 2017 record review screened 105 men receiving testosterone who were prescribed a three-peptide combination including sermorelin; 14 met the compliance criteria, and mean IGF-1 rose by about half over a mean of 134 days.[18] Sinha and colleagues wrote in 2020 that "a paucity of data examining the clinical effects of these compounds currently limits our understanding of GHS' role".[27]
Two 2026 reviews reach the same position. Dominikowski and colleagues catalog the reported adverse effects of GHRH analogs and secretagogues as "endocrine and metabolic disturbances (including prolactin and cortisol elevations, appetite changes, and dysglycaemia), fluid retention syndromes, musculoskeletal symptoms (myalgia/arthralgia), and injection-site reactions".[28] Vasylieva, West and Karpman, reviewing 76 studies, state that secretagogues "reliably increase growth hormone and insulin-like growth factor 1 concentrations; however, evidence for improved sexual function, physical performance, or quality of life remains limited", and that across the peptide classes reviewed "safety data are limited by short follow-up, small samples, and incomplete assessment of cardiovascular, metabolic, and oncologic outcomes".[29]
Documents a practice keeps on file
The sources above describe a record rather than a protocol, and the items a practice would keep on file follow from them.[1][7][19]
- The approval and withdrawal record: NDA 19-863 and NDA 20-443, the withdrawal effective 18 June 2009, and FDA's 2013 determination.
- The lists as of a stated date: 21 CFR 216.23, 21 CFR 216.24 and the 503A categories document (sermorelin absent) and the 503B categories document (sermorelin acetate in category 1 as a component of an approved drug).
- The pharmacy's certificate of analysis for the bulk sermorelin acetate it compounds with, which section 503A requires for each bulk drug substance.
- The IGF-1 monitoring the EGRIFTA SV label and the 2019 guideline describe, with the assay named, and the adverse events the trials and the label report.
Sermorelin reaches a practice through ExaVeyra's licensed 503A pharmacy partner on a patient-specific prescription, with a certificate of analysis available on request. Whether to prescribe, for which patient, and what to monitor are decisions for the prescribing practitioner.
This article summarizes publicly available federal regulation and peer-reviewed literature for licensed practitioner education. It is not legal advice, medical advice, or regulatory guidance, and it does not establish that any particular product or practice is compliant. Confirm current federal and state obligations with qualified counsel.
Annotated References
Numbered in the order they are cited in the text. Each source is annotated with what it supports on this page; peer-reviewed articles are listed with journal, volume, issue and pages, and primary sources are regulations, agency documents, guidelines and position statements.
- 1.RegulatoryFederal Register, Determination That GEREF (Sermorelin Acetate) Injection, 0.5 Milligrams Base/Vial and 1.0 Milligrams Base/Vial, and GEREF (Sermorelin Acetate) Injection, 0.05 Milligrams Base/Amp, Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness, 78 FR 14095 (4 March 2013, FR Doc. 2013-04827). Accessed 8 November 2026. https://www.federalregister.gov/documents/2013/03/04/2013-04827/determination-that-geref-sermorelin-acetate-injection-05-milligrams-basevial-and-10-milligrams
- 2.RegulatoryFederal Register, Novartis Pharmaceuticals Corp. et al.; Withdrawal of Approval of 92 New Drug Applications and 49 Abbreviated New Drug Applications, 74 FR 23407 (19 May 2009, FR Doc. E9-11628). Accessed 8 November 2026. https://www.federalregister.gov/documents/2009/05/19/E9-11628/novartis-pharmaceuticals-corp-et-al-withdrawal-of-approval-of-92-new-drug-applications-and-49
- 3.Peer-reviewedCorpas E, Harman SM, Piñeyro MA, Roberson R, Blackman MR. Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men. Journal of Clinical Endocrinology and Metabolism. 1992;75(2):530-535. https://pubmed.ncbi.nlm.nih.gov/1379256/Annotation: Ten healthy old men against nine young men, two strengths of GHRH(1-29) for 14 days each in random order: GH and IGF-I in the old men reached young values at the higher strength, with no change in fasting glucose, blood pressure or laboratory profiles.
- 4.Peer-reviewedKhorram O, Laughlin GA, Yen SS. Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)-NH2 in age-advanced men and women. Journal of Clinical Endocrinology and Metabolism. 1997;82(5):1472-1479. https://pubmed.ncbi.nlm.nih.gov/9141536/Annotation: Single-blind, randomized, placebo-controlled study of five months in 10 women and 9 men aged 55 to 71: GH and IGF-I rose then IGF-I drifted toward baseline by 16 weeks; skin thickness rose in both sexes; the only adverse effect was transient hyperlipidemia.
- 5.Peer-reviewedFalutz J, Mamputu JC, Potvin D, Moyle G, Soulban G, Loughrey H, Marsolais C, Turner R, Grinspoon S. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology and Metabolism. 2010;95(9):4291-4304. https://pubmed.ncbi.nlm.nih.gov/20554713/Annotation: Pooled phase 3 data in 806 antiretroviral-treated adults with HIV and excess abdominal fat: visceral fat treatment effect of minus 15.4 percent at 26 weeks, IGF-I increase, and no clinically meaningful glucose differences; the GHRH(1-44) description of the molecule.
- 6.Regulatory21 U.S.C. 353a, Pharmacy compounding (United States Code, 2024 edition, GPO). Accessed 8 November 2026. https://www.govinfo.gov/content/pkg/USCODE-2024-title21/html/USCODE-2024-title21-chap9-subchapV-partA-sec353a.htm
- 7.RegulatoryFDA, Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act (content current as of 14 May 2026). Accessed 8 November 2026. https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-under-section-503a-fdc-act
- 8.Peer-reviewedMolitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism. 2011;96(6):1587-1609. https://pubmed.ncbi.nlm.nih.gov/21602453/Annotation: The guideline statements that stimulation testing is usually required to confirm adult growth hormone deficiency and that the decision to treat requires individual benefit and risk evaluation.
- 9.RegulatoryFDA, Drugs@FDA, NDA 019863 GEREF (sermorelin acetate) injection. Accessed 8 November 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=019863
- 10.RegulatoryFDA, Drugs@FDA, NDA 020443 GEREF (sermorelin acetate) injection. Accessed 8 November 2026. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=020443
- 11.Regulatory21 CFR 216.24, Drug products withdrawn or removed from the market for reasons of safety or effectiveness (eCFR, current through 5 November 2026). Accessed 8 November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-B/section-216.24
- 12.Regulatory21 CFR 216.23, Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act (eCFR, current through 5 November 2026). Accessed 9 November 2026. https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-216/subpart-C/section-216.23
- 13.RegulatoryFDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories document, updated 14 May 2026). Accessed 8 November 2026. https://www.fda.gov/media/94155/download
- 14.RegulatoryFDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act (categories document, updated 21 March 2025). Accessed 8 November 2026. https://www.fda.gov/media/94164/download
- 15.Peer-reviewedPrakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999;12(2):139-157. https://pubmed.ncbi.nlm.nih.gov/18031173/Annotation: The chemistry statement that sermorelin is the 29-residue GHRH analog with full biological activity, the indirect pediatric height velocity comparison with somatropin (the recommended dosage was not compared directly), and the adverse events most commonly reported in children.
- 16.Peer-reviewedWalker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clinical Interventions in Aging. 2006;1(4):307-308. https://pubmed.ncbi.nlm.nih.gov/18046908/Annotation: A two-page editorial, with no new data, arguing that pituitary-mediated release stays under somatostatin feedback and is episodic; it closed by soliciting practitioners to study sermorelin under protocol.
- 17.Peer-reviewedBaker LD, Barsness SM, Borson S, Merriam GR, Friedman SD, Craft S, Vitiello MV. Effects of growth hormone-releasing hormone on cognitive function in adults with mild cognitive impairment and healthy older adults: results of a controlled trial. Archives of Neurology. 2012;69(11):1420-1429. https://pubmed.ncbi.nlm.nih.gov/22869065/Annotation: Randomized, double-blind, placebo-controlled 20-week trial of nightly tesamorelin in 152 adults, 66 with mild cognitive impairment: favorable cognitive effect, IGF-1 up 117 percent within the physiological range, fasting insulin up in the impaired group, and mild adverse events in 68 versus 36 percent.
- 18.Peer-reviewedSigalos JT, Pastuszak AW, Allison A, Ohlander SJ, Herati A, Lindgren MC, Lipshultz LI. Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels. American Journal of Men's Health. 2017;11(6):1752-1757. https://pubmed.ncbi.nlm.nih.gov/28830317/Annotation: Retrospective record review: 105 men screened, 14 meeting compliance criteria on a three-peptide combination including sermorelin; IGF-1 rose by about half; the statement that IGF-1 is the surrogate marker for GH.
- 19.Official sourceDailyMed, EGRIFTA SV (tesamorelin) kit, prescribing information, Theratechnologies Inc. Accessed 8 November 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3d783378-b02d-4f19-99dd-0fc91a042224
- 20.Peer-reviewedYuen KCJ, Biller BMK, Radovick S, Carmichael JD, Jasim S, Pantalone KM, Hoffman AR. American Association of Clinical Endocrinologists and American College of Endocrinology Guidelines for Management of Growth Hormone Deficiency in Adults and Patients Transitioning from Pediatric to Adult Care. Endocrine Practice. 2019;25(11):1191-1232. https://pubmed.ncbi.nlm.nih.gov/31760824/Annotation: The 58-recommendation update, its caution that GH and IGF-1 assays vary, and its discussion of unapproved uses of growth hormone in sports and aging.
- 21.Peer-reviewedClemmons DR. Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clinical Chemistry. 2011;57(4):555-559. https://pubmed.ncbi.nlm.nih.gov/21285256/Annotation: The Growth Hormone Research Society, IGF Society and IFCC workshop conclusion that major improvements are necessary in GH and IGF-I assay performance and comparability.
- 22.Peer-reviewedCorpas E, Harman SM, Blackman MR. Human growth hormone and human aging. Endocrine Reviews. 1993;14(1):20-39. https://pubmed.ncbi.nlm.nih.gov/8491152/Annotation: The National Institute on Aging group's framing of GHRH as a possible physiological approach and its statement that a great deal more research would be necessary.
- 23.Peer-reviewedVittone J, Blackman MR, Busby-Whitehead J, Tsiao C, Stewart KJ, Tobin J, Stevens T, Bellantoni MF, Rogers MA, Baumann G, Roth J, Harman SM, Spencer RG. Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men. Metabolism. 1997;46(1):89-96. https://pubmed.ncbi.nlm.nih.gov/9005976/Annotation: Eleven men aged 64 to 76 given one nightly GHRH(1-29) injection for six weeks: nocturnal GH rose, IGF-I did not, two of six strength measures improved, body composition did not change, and no significant adverse effects were observed.
- 24.Peer-reviewedKhorram O, Yeung M, Vu L, Yen SS. Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune system of aging men and women. Journal of Clinical Endocrinology and Metabolism. 1997;82(11):3590-3596. https://pubmed.ncbi.nlm.nih.gov/9360512/Annotation: Companion immunology report from the same 19 participants: increases in B cells, mitogen responsiveness and IL-2 receptor expression, with no adverse effects reported.
- 25.Peer-reviewedStanley TL, Feldpausch MN, Oh J, Branch KL, Lee H, Torriani M, Grinspoon SK. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380-389. https://pubmed.ncbi.nlm.nih.gov/25038357/Annotation: Six-month double-blind trial in 50 adults: reductions in visceral and liver fat, an early rise in fasting glucose that was no longer significant at six months.
- 26.Peer-reviewedSigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sexual Medicine Reviews. 2018;6(1):45-53. https://pubmed.ncbi.nlm.nih.gov/28400207/Annotation: The review's findings that few long-term, rigorously controlled studies exist, that blood glucose increases are a concern, and that long-term cancer incidence and mortality evaluation is needed.
- 27.Peer-reviewedSinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Translational Andrology and Urology. 2020;9(Suppl 2):S149-S159. https://pubmed.ncbi.nlm.nih.gov/32257855/Annotation: The statement that a paucity of data on the clinical effects of sermorelin and the other secretagogues limits understanding of their role.
- 28.Peer-reviewedDominikowski A, Rękoś Z, Olejarz M, Szczepanek-Parulska E, Domin R, Ruchała M. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Frontiers in Endocrinology. 2026;17:1822475. https://pubmed.ncbi.nlm.nih.gov/42395176/Annotation: The catalog of reported adverse effects across GHRH analogs and secretagogues, and the evidence-tier table that codes sermorelin A* for historical FDA approval in pediatric GHD, with no current approval for performance or body-composition use.
- 29.Peer-reviewedVasylieva V, West A, Karpman E. Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. Sexual Medicine Reviews. 2026;14(4):qeag078. https://pubmed.ncbi.nlm.nih.gov/42862021/Annotation: Structured search of 76 studies: secretagogues reliably raise GH and IGF-1, evidence for functional outcomes remains limited, and safety data are limited by short follow-up and small samples.
Cite this page
ExaVeyra Sciences Editorial Team. Sermorelin: Approval History and Trials. ExaVeyra Sciences; 9 November 2026. Available from: https://exaveyra.com/science/compounds/sermorelin-approval-history-and-trials. Accessed [date accessed].